-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Food and Drug Administration
Fourth Annual Deep Brain Stimulation (DBS) Think Tank (Frontiers in Integrative Neuroscience / International Journal of Neuroscience)
Summary An annual round-up of developments in the field of Deep Brain Stimulation (DBS). (x3). Full Text Link Reference Deeb, W. Giordano, JJ. [and] Rossi, PJ. [et al] (2016). Proceedings of the Fourth Annual Deep Brain Stimulation Think Tank: a … Continue reading →
Posted in Depression, For Doctors (mostly), For Researchers (mostly), International, Mental Health, Non-Pharmacological Treatments, Parkinson's Disease, Quick Insights
|
Tagged Allegheny General Hospital Pittsburgh, Alpert Medical School: Brown University Providence, Alzheimer's Disease, Asia Pacific Centre for Neuromodulation: Queensland Brain Institute, Barrow Neurological Institute: St. Joseph's Hospital and Medical Center, Basolateral Nucleus of the Amygdala, Baylor College of Medicine Houston, Brown University Providence, Center for Movement Disorders and Neurorestoration: University of Florida, Center for Neuromodulation: New York University Langone Medical Center New York, Centers for Medicare and Medicaid Services, Centromedian Thalamus, Clinical Assessment and Management of Tremor, Closed Loop Systems, Closed-Loop DBS, Crayton Pruitt Family Department of Biomedical Engineering: University of Florida, DARPA-SUBNETS: Defense Advanced Research Projects Agency - Systems-Based Neurotechnology for Emerging Therapies, Deep Brain Stimulation, Deep Brain Stimulation (DBS), Deep Brain Stimulation for the Treatment of Alzheimer Disease, Deep Brain Stimulation for the Treatment of Dementia, Deep Brain Stimulation in Parkinson's Disease, Defense Advanced Research Projects Agency (Darpa), Department of Bioengineering, Department of Biomedical Engineering: Duke University, Department of Neurology and Neuroethics Studies Program: Georgetown University Medical Center Washington, Department of Neurology: Alpert Medical School Brown University Providence, Department of Neurology: Baylor College of Medicine Houston, Department of Neurology: Mayo Clinic (Rochester), Department of Neurology: New York University Langone Medical Center New York, Department of Neurology: University Clinic of Würzburg, Department of Neurology: University of California San Francisco, Department of Neurology: University of Florida, Department of Neurosurgery: New York University Langone Medical Center New York, Department of Neurosurgery: University of Kentucky Chandler Medical Center Lexington, Department of Psychiatry: Massachusetts General Hospital Boston, Departments of Neurological Sciences: Rush University Medical Center Chicago, Diffusion Tensor Imaging, Drug Addiction, Duke University, Electrical Current Shaping, Electrocorticogram, Emory University School of Medicine (Atlanta), Epilepsy, Fludeoxyglucose, Focused Ultrasound, Food and Drug Administration, Fourth Annual Deep Brain Stimulation (DBS) Think Tank, Frontiers in Integrative Neuroscience, Georgetown University Medical Center Washington, Germany, High Frequency Stimulation, Humanitarian Device Exemption, International Deep Brain Stimulation Registry and Database for Gilles de la Tourette Syndrome, International Journal of Neuroscience, Investigational Device Exemption, Johns Hopkins Bayview Medical Center, Johns Hopkins School of Medicine Baltimore, Johns Hopkins University School of Medicine Baltimore, Kavli Institute for Fundamental Neuroscience: University of California, Local Field Potential, Local Field Potentials (LFPs), Low Frequency Stimulation, Massachusetts General Hospital (Boston), Mayo Clinic: Rochester, MCI: Mild Cognitive Impairment, Medial Prefrontal Cortex, Medtronic Modulation Minneapolis (USA), Mild Cognitive Impairment (MCI), Movement Disorders Program: Alpert Medical School, National Neurotechnology Initiative, Netherlands, Neurodegeneration, Neurodegenerative Diseases, Neuroimaging, Neuroimaging of Dementia, Neurological Disease, Neurological Information Non-Discrimination Act, Neurology, Neuropsychology, New York University: Langone Medical Center New York, NSF Engineering Research Center for Sensorimotor Neural Engineering (Seattle), Obesity, Obsessive-Compulsive Disorder, Pellegrino Center for Clinical Bioethics: Georgetown University Medical Center Washington, Post-Traumatic Stress Disorder, Psychiatry and Behavioral Sciences: Johns Hopkins Bayview Medical Center, Queensland Brain Institute: University of Queensland Brisbane, Responsive Neurostimulator, Rhode Island Hospital, Rush University Medical Center: Chicago, Scientific Computing and Imaging Institute: University of Utah Salt Lake City, Second Annual Deep Brain Stimulation (DBS) Think Tank, St. Joseph's Hospital and Medical Center, Stanford University, Stroke, Subcallosal Cingulate, Subthalamic Nucleus, Third Annual Deep Brain Stimulation (DBS) Think Tank, Tourette Syndrome (TS), Transdiagnostic Restoration of Affective Networks by System Identification and Function Oriented Real-Time Modeling in Deep Brain Stimulation, Treatment Resistant Depression, United States, University of Alabama at Birmingham, University of Amsterdam, University of California, University of California San Francisco, University of Florida, University of Kentucky Chandler Medical Center Lexington, University of Queensland Brisbane, University of Utah Salt Lake City, University of Washington (Seattle), USA, VA Greater Los Angeles Healthcare System, Viability of a DBS Industry Roadmap and Consortium
|
Leave a comment
Challenges in Developing Disease-Modifying Treatments for Dementia (Department of Health)
Summary Raj Long, the Senior Regulatory Officer at the Bill & Melinda Gates Foundation, explores the problems in developing treatments for dementia. The independent “Finding a Path for the Cure for Dementia” report is a contribution to the G8 Dementia … Continue reading →
Posted in Charitable Bodies, Commissioning, Department of Health, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Standards, UK, Universal Interest
|
Tagged Academia-Industry Partnerships, Academic Research, AIFA: Italian Medicines Agency, Attrition Analysis, BfArM: Federal Institute of Drugs and Medical Devices, BfArM: Federal Institute of Drugs and Medical Devices (Germany), Bill and Melinda Gates Foundation, Biopharmaceutical Companies, Burden of Dementia, Canada, CEOi: Global CEO Initiative on Alzheimer’s Disease, Challenge on Dementia (David Cameron), Charitable Funding, Clinical Trial Efficiencies, Collaboration, Collaborative Projects, Composite End Points, Consistent Global Development Pathways, Cross-Sector Partnerships, CTEG: Clinical and Technical Expert Group, Danish Health and Medicines Authority, Data Sharing, Dementia Challenge, Dementia Research, Dementia Research Funding, Dementia Research Priorities, Dementia Research: UK Impact, Denmark, Department of Health Dementia Challenge, Diagnosis and Referral, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DKMA: Danish Health and Medicines Authority, Drug Discovery Programmes, Drug Identification, Drug Regulation, Drug-Development Pipeline, Eli Lilly Inc., Eli Lilly’s UK Dementia Research Centre, EMA: European Medicines Agency, European Medicines Agency, European Union, FIH: First in Humans, Financial Incentives, First Global Ministerial Conference on Global Action Against Dementia, Food and Drug Administration, G20 Countries, G7 Countries, G8 Dementia Summit: Global Action Against Dementia, G8 Summit, Gaps in the Basic Science, Germany, Global Alzheimer’s and Dementia Action Alliance (GADAA), Global Envoy for Dementia Innovation, Global Leadership, Global Outlook, Global Social Investment for Dementia, Government Research Funding, Health Canada, IAP Steering Committee, IDAP Steering Committee, IDAP: International Dementia Advisory Platform, IFPMA: International Federation of Pharmaceutical Manufacturers & Associations, Incentives and Investment, Incentives for Drug Development, Independent Safety Review Committee, Integrated Development Pathway, International Collaborations, International Dementia Advisory Platform (IDAP), International Dementia Research Inventories, International Programmes, Italian Medicines Agency, Italy, Japan, Japan: Pharmaceuticals and Medical Devices (Japan), Knowledge Translation, MEB: Medicines Evaluations Board, Medicines and Healthcare Products Regulatory Agency, Medicines Evaluation Board Netherlands, MHRA: Medicines and Healthcare Products Regulatory Agency, Modelling and Extrapolation, Multilateral Cooperation, Multilateral Regulator Cooperation, Netherlands, Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurological Research, OHE: Office of Health Economics, Open Access Databases, Open Access Knowledge Resources, Open Access Research, Open Science, Organisation for Economic Co-operation and Development (OECD), Organisation for Economic Co-operation and Development (OECD) Countries, Organisation for Economic Cooperation and Development, Partnership, Partnership and Collaboration, Partnership Working, Patient Viewpoint, Philanthropic Funding, Pipeline Databases, PMDA: Pharmaceutical and Medicines Devices Agency, Public-Private Partnership (PPP), Quantifiable Reproducible Outcome Measures, Raj Long: Senior Regulatory Officer for Integrated Development in Global Health at the Bill & Melinda Gates Foundation, Reasons for Termination of Trials, Regulator Perspectives, Regulatory Agencies, Regulatory Experts, Research and Developers’ Status Quo, Research and Development, Research and Innovation, Research Commitment, Research Funding, Research Status Quo, Resource and Incentives, Risk Benefit Balance, Standardisation and Validation of Cognitive Endpoints, Swiss Medic, Switzerland, United States, WDC: World Dementia Council, World Dementia Council, World Health Organisation (WHO)
|
Leave a comment
